Skip to content
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Endocrinology · Primary Bilateral Macronodular Adrenal Hyperplasia

Understanding Your Diagnosis: PBMAH and BMAD

At a Glance

PBMAH and BMAD describe nodules in both adrenal glands; the nodules may be nonfunctional or may produce cortisol independently of ACTH. Cortisol and ACTH testing, imaging, and sometimes genetic evaluation help determine whether monitoring, medication, or surgery is appropriate.

Receiving a diagnosis of Primary Bilateral Macronodular Adrenal Hyperplasia (PBMAH) can feel overwhelming, especially because the name itself is a mouthful and the condition is quite rare. If you are like many people with this condition, you may have discovered it “by accident” during a CT scan or MRI for an unrelated issue, such as back pain or a digestive problem [1].

This page will help you understand what is happening in your body and why your medical team might be using different names to describe the same thing.

Understanding the Name Change

In the world of medicine, names for diseases often change as scientists learn more about them. You may hear several different terms:

  • PBMAH: Primary Bilateral Macronodular Adrenal Hyperplasia. This has been the standard name for years.
  • BMAD: Bilateral Macronodular Adrenal Disease.
  • BMACD: Bilateral Macronodular Adrenal Cortical Disease.

In 2022, the World Health Organization (WHO) updated its classification framework to group macronodular and micronodular lesions under adrenal cortical nodular disease, including BMACD and BMAD [2][3]. This change reflects a new understanding that the “lumps” on the adrenal glands are not just simple overgrowth (hyperplasia), but are specific nodules that can have their own genetic signatures [4][5]. Whether your doctor calls it PBMAH or BMAD, they are referring to the same bilateral nodular condition [6][7]. It is important to know that BMAD/PBMAH describes the structural disease on your glands; your actual cortisol autonomy is assessed separately, as some patients have nonfunctional nodules.

How Common is This?

PBMAH is a rare cause of Cushing syndrome (the state of having too much cortisol in the body). It accounts for less than 2% of all Cushing syndrome cases [8][9].

However, because imaging technology is becoming so advanced, doctors are finding these “adrenal incidentalomas” more frequently. Among people who have nodules on both adrenal glands discovered incidentally, about one-third may be found to have PBMAH/BMAD when cortisol excess is present [1][10]. While it is rare in the general population, it is a well-recognized condition among adrenal specialists.

What Does ‘ACTH-Independent’ Mean?

In a healthy body, a small gland at the base of the brain called the pituitary gland acts like a thermostat. It sends out a hormone called ACTH (Adrenocorticotropic Hormone) to tell the adrenal glands when to make cortisol.

In functional PBMAH, the “thermostat” is broken, but not in the brain. Instead, the adrenal glands themselves have become “autonomous.” This is called ACTH-independent cortisol production [11].

  • The adrenal nodules make cortisol on their own, without waiting for a signal from the brain [12].
  • Because there is already extra cortisol in your blood, your brain correctly senses the “heat” and stops sending out the ACTH signal.
  • As a result, your blood tests will typically show cortisol levels that fail to suppress normally and very low or suppressed ACTH levels [11]. Low ACTH supports adrenal autonomy, though it does not by itself prove PBMAH or exclude every other cause.

Why Are Both Glands Affected?

Unlike a single adrenal tumor, PBMAH affects both glands. This is often due to genetic factors that make the adrenal tissue more likely to grow nodules.

One of the most significant discoveries in this field is the ARMC5 gene. Many people with PBMAH have a germline mutation in this gene that can be inherited from a parent [13]. This mutation acts like a “first hit” to the adrenal glands, making them susceptible. Over time, individual nodules may undergo a “second hit” or further genetic changes, causing them to grow and begin pumping out excess cortisol [14][5].

“Misplaced” Signals

In some people with BMAD, the adrenal glands develop “aberrant receptors.” Essentially, the glands start listening to the wrong signals. For example, instead of listening to ACTH, the adrenal glands might start responding to:

  • GIP (Gastric Inhibitory Polypeptide): A hormone released by your gut when you eat. This can cause cortisol levels to spike specifically after meals [15].
  • Vasopressin: A hormone that regulates water balance.
  • Posture: Some people’s adrenal glands may even release cortisol in response to standing up or changing positions [11].

Navigating the Emotional Impact

It is completely normal to feel a mix of confusion and anxiety after this diagnosis. Because it is often found incidentally, you may have gone into a scan for a minor issue and come out with a diagnosis of a rare condition [16].

The range of the disease is very broad. Some people have “overt” Cushing syndrome with clear physical symptoms, while others have “mild autonomous cortisol secretion” (MACS), where the cortisol fails to suppress on lab tests but isn’t yet causing obvious physical changes [17][18]. This “gray area” can be frustrating, as you and your doctor must decide whether to monitor the nodules or move toward treatment, such as surgery or medication [19][20].

Remember that an incidental finding is a starting point, not a final destination. Your medical team will use hormone tests and specialized imaging to create a plan that fits your specific cortisol levels and symptoms [19].

Common questions in this guide

Are PBMAH and BMAD different diseases?
No. PBMAH, BMAD, and BMACD are different names used for the same type of nodular disease affecting both adrenal glands. The terms describe the gland changes, while separate hormone testing shows whether the nodules are making too much cortisol.
Does having PBMAH mean I have Cushing syndrome?
Not necessarily. Some bilateral adrenal nodules do not make excess cortisol, while others cause mild autonomous cortisol secretion or overt Cushing syndrome. Your clinician uses cortisol testing, ACTH levels, symptoms, and imaging to assess how active the disease is.
What does ACTH-independent cortisol production mean?
It means the adrenal nodules are making cortisol without waiting for the pituitary gland to send an ACTH signal. Because cortisol is already high, ACTH is often low or suppressed, and cortisol may not decrease as expected on suppression testing. A low ACTH level supports adrenal autonomy but does not by itself prove PBMAH.
Can PBMAH run in families?
Yes, some people with PBMAH have an inherited change in the ARMC5 gene, which can make adrenal nodules more likely to develop. Genetic counseling can help you understand whether testing is appropriate and what a result could mean for relatives. Not every person with PBMAH has an ARMC5 change.
What symptoms can bilateral adrenal nodules cause?
Some people have no obvious physical changes, especially when cortisol excess is mild. When cortisol is clearly elevated, possible symptoms include unexplained weight gain, high blood pressure, and muscle weakness. Your medical team will compare symptoms with hormone results rather than relying on symptoms alone.
How is PBMAH treated or monitored?
The plan depends on cortisol production, symptoms, and the size and appearance of the adrenal glands. Some people are monitored with hormone tests and imaging, while others may need medication or surgery to address cortisol excess. Your endocrinology team can explain which approach fits your findings.

Get notified when new evidence is published on Cushing syndrome due to bilateral macronodular adrenocortical disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (20)
  1. 1

    Prevalence and phenotype of primary bilateral macronodular adrenal hyperplasia with autonomous cortisol secretion: a study of 98 patients.

    Bengoa-Rojano N, Fernández-Argüeso M, Botella-Carretero JI, et al.

    Revista clinica espanola 2022; (222(8)):458-467 doi:10.1016/j.rceng.2022.01.003.

    PMID: 35597729
  2. 2

    Overview of the 2022 WHO Classification of Adrenal Cortical Tumors.

    Mete O, Erickson LA, Juhlin CC, et al.

    Endocrine pathology 2022; (33(1)):155-196 doi:10.1007/s12022-022-09710-8.

    PMID: 35288842
  3. 3

    Bilateral macronodular and micronodular hyperplasia: Biochemical, radiological and genetic diagnosis.

    Navas-Moreno V, Sager-La Ganga C, Tapia-Sanchiz MS, et al.

    Vitamins and hormones 2026; (132()):93-126 doi:10.1016/bs.vh.2026.02.002.

    PMID: 42236017
  4. 4

    KDM1A pathogenic variants link epigenetic regulation to GIP-dependent primary bilateral macronodular adrenal hyperplasia.

    Chasseloup F, Kamenický P

    Annales d'endocrinologie 2026; (87(3)):102516 doi:10.1016/j.ando.2026.102516.

    PMID: 41864332
  5. 5

    Primary Bilateral Macronodular Adrenocortical Disease With Concomitant Cushing Syndrome and Primary Aldosteronism Harboring Distinct ARMC5 Mutations in Individual Nodules.

    Kitazawa S, Kitazawa R

    Cureus 2026; (18(1)):e102743 doi:10.7759/cureus.102743.

    PMID: 41631058
  6. 6

    Cushing´s syndrome due to bilateral adrenal cortical disease: Bilateral macronodular adrenal cortical disease and bilateral micronodular adrenal cortical disease.

    Araujo-Castro M, Marazuela M

    Frontiers in endocrinology 2022; (13()):913253 doi:10.3389/fendo.2022.913253.

    PMID: 35992106
  7. 7

    Bilateral Adrenocortical Nodular Disease and Cushing's Syndrome.

    Bouys L, Violon F, Louiset E, et al.

    The Journal of clinical endocrinology and metabolism 2024; (109(10)):2422-2432 doi:10.1210/clinem/dgae419.

    PMID: 38888184
  8. 8

    Primary bilateral macronodular adrenal hyperplasia: A series of 32 cases and literature review.

    Araujo-Castro M, Reincke M

    Endocrinologia, diabetes y nutricion 2023; (70(4)):229-239 doi:10.1016/j.endien.2023.04.005.

    PMID: 37116968
  9. 9

    Primary bilateral macronodular adrenal hyperplasia: A rare case report of Cushing syndrome and review of literature.

    Ghanbari Boroujeni MR, Meftah E, Zarimeidani F, et al.

    Medicine 2024; (103(41)):e40050 doi:10.1097/MD.0000000000040050.

    PMID: 39465833
  10. 10

    Clinical, Pathophysiologic, Genetic, and Therapeutic Progress in Primary Bilateral Macronodular Adrenal Hyperplasia.

    Bertherat J, Bourdeau I, Bouys L, et al.

    Endocrine reviews 2023; (44(4)):567-628 doi:10.1210/endrev/bnac034.

    PMID: 36548967
  11. 11

    Diagnosis and management of primary bilateral macronodular adrenal hyperplasia

    Vassiliadi DA, Tsagarakis S

    Endocrine-related cancer 2019; (26(10)):R567-R581.

    PMID: 32053747
  12. 12

    An Overview of the Heterogeneous Causes of Cushing Syndrome Resulting From Primary Macronodular Adrenal Hyperplasia (PMAH).

    Charchar HLS, Fragoso MCBV

    Journal of the Endocrine Society 2022; (6(5)):bvac041 doi:10.1210/jendso/bvac041.

    PMID: 35402764
  13. 13

    Whole-genome sequencing revealed armadillo repeat containing 5 (ARMC5) mutation in a Chinese family with ACTH-independent macronodular adrenal hyperplasia.

    Zhang Q, Cui L, Gao JP, et al.

    Endocrine journal 2018; (65(3)):269-279 doi:10.1507/endocrj.EJ17-0317.

    PMID: 29279458
  14. 14

    The ARMC5 gene shows extensive genetic variance in primary macronodular adrenocortical hyperplasia.

    Correa R, Zilbermint M, Berthon A, et al.

    European journal of endocrinology 2015; (173(4)):435-40 doi:10.1530/EJE-15-0205.

    PMID: 26162405
  15. 15

    Extensive expertise in endocrinology: glucose-dependent insulinotropic peptide-dependent Cushing's syndrome.

    Lacroix A

    European journal of endocrinology 2023; (188(3)):R56-R72 doi:10.1093/ejendo/lvad026.

    PMID: 36857084
  16. 16

    Diagnostic pitfalls of adrenal incidentaloma.

    Cyrańska-Chyrek E, Grzymisławska M, Ruchała M

    Endokrynologia Polska 2017; (68(3)):360-377 doi:10.5603/EP.2017.0028.

    PMID: 28660993
  17. 17

    Genetic background and management outcomes in primary bilateral macronodular adrenal hyperplasia: Implications for diagnosis and treatment-A retrospective cohort study.

    Gür EÖ, Karaıslı S, Çavdar Ü, et al.

    The Journal of international medical research 2026; (54(3)):3000605261430449 doi:10.1177/03000605261430449.

    PMID: 41871980
  18. 18

    Recent Updates on the Management of Adrenal Incidentalomas.

    Park SS, Kim JH

    Endocrinology and metabolism (Seoul, Korea) 2023; (38(4)):373-380 doi:10.3803/EnM.2023.1779.

    PMID: 37583083
  19. 19

    Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors.

    Fassnacht M, Arlt W, Bancos I, et al.

    European journal of endocrinology 2016; (175(2)):G1-G34 doi:10.1530/EJE-16-0467.

    PMID: 27390021
  20. 20

    A multidisciplinary approach to the management of adrenal incidentaloma.

    Voltan G, Boscaro M, Armanini D, et al.

    Expert review of endocrinology & metabolism 2021; (16(4)):201-212 doi:10.1080/17446651.2021.1948327.

    PMID: 34240680

This page is for informational purposes only and does not constitute medical advice. Your endocrinology team should interpret your cortisol, ACTH, imaging, and genetic results and discuss whether monitoring or treatment is right for you.